BIRMINGHAM, Ala. – April 6, 2015 – Alan Stokes, Ph.D., today joined Southern Research’s drug development division as the director of toxicology and pathology at its Birmingham headquarters. In this role, Stokes will manage groups of toxicologists, laboratory technicians, project team members, and formulation scientists for contracted studies in support of drug development activities.
“We are extremely pleased to have Dr. Stokes join the Southern Research drug development team,” said Andrew Penman, vice president of drug development at Southern Research. “He is bringing with him invaluable experience both in interacting with regulatory agencies and representing the non-clinical toxicology function for therapeutics at all stages of development.”
Stokes has more than 14 years of combined experience in pharmaceutical drug development for leading pharmaceutical companies including Schering-Plough, Wyeth Consumer Healthcare, and most recently, GlaxoSmithKline, where he was head of toxicology at Research Triangle Park, North Carolina.
He is a diplomate to the American Board of Toxicology, and he is a member of the Society of Toxicology, the American College of Toxicology, and the editorial board for the International Journal of Toxicology.
Stokes earned a doctorate in pharmacology with a focus on neurotoxicity from Wake Forest University and completed a post-doctoral fellowship at the Robert Wood Johnson Medical School Department of Neurology at Rutgers University.
About Southern Research
Founded in 1941 in Birmingham, Alabama, Southern Research is a not-for-profit 501(c)(3) scientific and engineering research organization that conducts preclinical drug discovery and development, advanced engineering research in materials, systems development, and energy and environment research. Approximately 500 team members support clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental, and energy industries in facilities in Alabama, Maryland, North Carolina, Georgia, and Texas.